Please assess the completion status of the following clinical trial:

Trial Title: CONVERGE - Epi/Endo Ablation For Treatment of Persistent Atrial Fibrillation(AF)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 years; \< 80 years~* Left atrium \< 6.0 cm~* Refractory or intolerant to one AAD (class I and/or III)~* Documentation of persistent AF~* Provided written informed consent~Exclusion Criteria:~* Patients requiring concomitant surgery~* Left ventricular ejection fraction \< 40%~* Pregnant or planning to become pregnant during study~* Co-morbid medical conditions that limit one year life expectancy~* Previous cardiac surgery~* History of pericarditis~* Previous cerebrovascular accident (CVA), excluding fully resolved transient Ischemic attack (TIA)~* Patients who have active infection or sepsis~* Patients with esophageal ulcers strictures and varices~* Patients with renal dysfunction who are not on dialysis~* Patients who are contraindicated for anticoagulants~* Patients who are being treated for ventricular arrhythmias~* Patients who have had a previous left atrial catheter ablation for AF~* Patients with existing Implantable Cardioverter-Defibrillator (ICDs)~* Current participation in another clinical investigation of a medical device or a drug, or recent participation in such a study within 30 days prior to study enrollment~* Not competent to legally represent him or herself

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Convergent Procedure (Type: EXPERIMENTAL): Procedure/Surgery: Convergent Procedure using EPi-Sense-AF Guided Coagulation System with Endocardial Catheter Ablation Treatment
- Standalone Endocardial Catheter Ablation (Type: ACTIVE_COMPARATOR): Procedure/Surgery: Endocardial Catheter Ablation Treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).